Emcure Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cuombu69cd6nocrjw8mbnbik.pdf

Key Takeaways


The Novo Nordisk Partnership & Obesity Entry

Satish Mehta: "The partnership gives us an early entry in the obesity market versus the rest of the competition and positions Emcure to shape it."

Domestic Business

Vikas Thapar: "post-LOE, we anticipate a very crowded market in India. And so the ability to partner with Novo and launch this brand ahead of the competition and allowing ourselves to shape the market and have brand recall versus being lost in the crowd probably 4, 5 months down the line is something that we feel strongly will allow us to succeed."

International Markets


Margins & Profitability


Balance Sheet & Capital Allocation


Pipeline & In-Licensing Strategy

Satish Mehta: "So to that extent, the bias always be in terms of ensuring that we don't become disproportionately from, what I would say, dependent on the in-licensing deals. Our endeavour is obviously to get products from our R&D and make our brands bigger."

Guidance & Commitments

CommitmentSpecificsTimeline
Base margin expansion~150 bps improvement, excluding Sanofi diabetes and Novo dealFY26
Debt-freeNet debt zeroEnd of FY27 (18-24 months)
Organic domestic growthIndustry growth rate + 100-200 bpsOngoing
Amphotericin B launchesFrance, Germany and other Western European countriesRemaining part of FY26
Semaglutide Canada filingFile for approval in CanadaEnd of FY26
Inventory normalizationInventory built for launches to normalizeNext 6 months
In-licensing margin thresholdMid-teens EBITDA margin dealsOngoing

Key Metrics

MetricQ2 FY26
Revenue from operations₹2,270 cr, up 13.4% YoY from ₹2,002 cr in Q2 FY25
Domestic business revenue₹1,031 cr, up 10.6% YoY
International business revenue₹1,238 cr, up 15.8% YoY
Europe revenue₹444 cr, up 22.7% YoY
Canada revenue₹348 cr, up 17.5% YoY
Emerging markets revenue₹446 cr, up 8.6% YoY
Gross margin60.8%, versus 60.6% in Q2 FY25
EBITDA (excl. other income)₹439 cr, up 15.2% YoY
EBITDA margin19.3%, versus 19% in Q2 FY25 and 19.2% in Q1 FY26
Profit after tax₹251 cr, up 24% YoY, highest quarterly profit
Net debt₹837 cr
Domestic organic growth (excl. Sanofi diabetes)8.5%–9%
Effective tax rate26%
Depreciation and amortization₹105 cr
Interest cost₹33 cr